PepScribe

Guide · Dosing

Tirzepatide dosage chart in units. - Reddit

Last updated July 1, 2026

More: Clinical standards · Pharmacy partners

The single most common source of confusion for people starting compounded tirzepatide is the relationship between milligrams and units. Your prescription reads in milligrams; your syringe measures in units. The tirzepatide dosage chart in units bridges that gap — but because vial concentrations vary by pharmacy, understanding the math matters more than memorizing a single table.

Quick answer

A tirzepatide dosage chart in units converts your prescribed mg dose to a syringe draw using this formula: Units = (mg dose ÷ mg/mL concentration) × 100. At 10 mg/mL: 2.5 mg = 25 units, 5 mg = 50 units, 10 mg = 100 units, 15 mg = 150 units. At 5 mg/mL those values double. Because 503A compounding pharmacies use different concentrations, the authoritative reference is always the label on your specific vial — not a generic chart.

Key takeaways

  • A dosage chart converts mg to draw volume using Units = (mg dose ÷ mg/mL) × 100 on a U-100 insulin syringe.
  • At 10 mg/mL: 2.5 mg = 25 units, 5 mg = 50 units, 10 mg = 100 units, 15 mg = 150 units. At 5 mg/mL those values double.
  • Because 503A pharmacies use different concentrations, your vial labelis the authoritative reference — a generic chart is not.
  • The standard titration ladder steps up 2.5 mg every 4 weeks from 2.5 mg to a 15 mg maximum, adjusted by your clinician.
  • Drawing the wrong volume over- or under-doses you — if uncertain, contact your clinician or pharmacy before injecting.

A supervised tirzepatide program includes clinician check-ins precisely so dose questions get answered, not guessed.

Take the free assessment

Why are tirzepatide units and milligrams different measurements?

Tirzepatide is prescribed by weight — milligrams (mg) of active peptide per injection. But insulin syringes (the standard tool for subcutaneous peptide injections) are marked in units, where 1 mL equals 100 units. The dose you draw in units depends on how concentrated your specific vial is.

Compounded tirzepatide is prepared by licensed 503A pharmacies in the United States, compounded in the USA by licensed 503A pharmacies with no hidden overseas supply chain. These pharmacies formulate to your clinician’s prescription, which specifies a concentration — commonly 5 mg/mL or 10 mg/mL, though other concentrations exist. That concentration determines how much liquid volume you draw to deliver your milligram dose.

The conversion formula

The arithmetic is straightforward once you know your vial’s concentration:

  1. Find your concentration.It is printed on your pharmacy label in mg/mL (e.g., “10 mg/mL”).
  2. Divide dose by concentration. Prescribed dose (mg) ÷ concentration (mg/mL) = volume in mL. Example: 5 mg ÷ 10 mg/mL = 0.5 mL.
  3. Convert mL to units. Volume (mL) × 100 = units. Example: 0.5 mL × 100 = 50 units.

Your clinician and pharmacist should confirm this calculation before your first injection. Never adjust your draw volume based on a chart found online without cross-referencing it against your actual pharmacy label.

Reference chart: common concentrations

The table below shows unit volumes for common tirzepatide doses at two frequently dispensed concentrations. Verify that your pharmacy label matches the concentration column before using these values.

Dose (mg)5 mg/mL → units10 mg/mL → units
2.5 mg50 units (0.5 mL)25 units (0.25 mL)
5 mg100 units (1.0 mL)50 units (0.5 mL)
7.5 mg150 units (1.5 mL)75 units (0.75 mL)
10 mg200 units (2.0 mL)100 units (1.0 mL)
12.5 mg250 units (2.5 mL)125 units (1.25 mL)
15 mg300 units (3.0 mL)150 units (1.5 mL)

Note: Volumes above 1 mL at 5 mg/mL may require a larger syringe. Discuss syringe selection with your pharmacy.

The same milligram dose maps to a different number of units depending on your vial’s concentration — the pharmacy label is the only reference that counts.

What is the standard tirzepatide titration ladder?

Clinician-supervised weight management protocols with tirzepatide typically follow a slow titration to allow the body to adapt and minimize GI side effects. The most common schedule, mirroring the labeled dose escalation studied in trials, is:

  • Weeks 1–4: 2.5 mg once weekly
  • Weeks 5–8: 5 mg once weekly
  • Weeks 9–12: 7.5 mg once weekly
  • Weeks 13–16: 10 mg once weekly
  • Weeks 17–20: 12.5 mg once weekly
  • Week 21+: 15 mg once weekly (maximum)

This is a reference schedule. Your clinician may extend any step if side effects are significant, or hold a dose increase if you haven’t achieved expected tolerability. Some patients respond well at lower doses and remain there long-term. The prescribing clinician makes those calls based on individual response, not the titration table.

Draw accuracy and syringe selection

Most subcutaneous tirzepatide injections use 1 mL insulin syringes (U-100 syringes). At a 10 mg/mL concentration, all standard doses up to 10 mg fit within 1 mL. At 5 mg/mL, doses above 5 mg exceed 1 mL and may require a larger syringe.

Accurate draw technique matters. Pull the plunger to your target unit mark, then check for air bubbles — tap the syringe and push air out before injecting. Off-by-one unit errors at 2.5 mg (25 units at 10 mg/mL) represent a 4% overdose, which is clinically minor; but at higher doses with less concentrated vials, the same absolute error represents a larger percentage deviation.

What to do if you’re uncertain

If you are unsure about your draw volume, contact your prescribing clinician or your compounding pharmacy before injecting. Both are obligated to clarify your dosing instructions. A brief phone call eliminates the margin for error that a dosage chart alone cannot.

Compounded tirzepatide dispensed through a supervised telehealth program — like the one PepScribe connects patients to — includes clinician check-ins precisely for this reason. Dose questions belong in that conversation, not in a forum thread.

Frequently asked questions

What does a tirzepatide dosage chart in units actually show?

A tirzepatide dosage chart in units maps milligram doses to the injection volume (in units or milliliters) drawn from a reconstituted vial. Because compounded tirzepatide vials vary in concentration — commonly 5 mg/mL, 10 mg/mL, or higher — the unit volume for the same milligram dose changes depending on your specific vial. Your pharmacy label is the authoritative source for your draw volume; a generic chart is a reference, not a prescription.

What is the standard tirzepatide titration schedule?

Most clinician-supervised protocols for weight management start at 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg per week. Your clinician may adjust this schedule based on GI tolerability and individual response.

How many units is 2.5 mg of tirzepatide at 10 mg/mL?

At a concentration of 10 mg/mL, a 2.5 mg dose equals 0.25 mL. In standard insulin-syringe units (where 1 mL = 100 units), that is 25 units. At 5 mg/mL, the same 2.5 mg dose would be 0.5 mL or 50 units. Always verify the concentration printed on your pharmacy label before drawing.

Can I calculate my own tirzepatide dose in units?

The arithmetic is straightforward: divide your prescribed milligram dose by the vial concentration in mg/mL to get the volume in mL, then multiply by 100 to convert to insulin-syringe units. Example: 5 mg ÷ 10 mg/mL = 0.5 mL × 100 = 50 units. However, your clinician and pharmacist should confirm this calculation before your first injection.

Why do compounded tirzepatide concentrations vary?

Licensed 503A compounding pharmacies prepare tirzepatide to patient-specific prescriptions. A clinician may specify a concentration that suits the prescribed dose range, minimizes injection volume, or matches the patient's titration schedule. There is no single universal concentration — your vial label is the only accurate reference for your protocol.

What happens if I draw the wrong volume?

Drawing too much delivers a higher dose than prescribed, which increases the risk of GI side effects (nausea, vomiting, diarrhea) and may accelerate dose escalation faster than intended. Drawing too little delivers a subtherapeutic dose. If you are uncertain about your draw volume, contact your prescribing clinician or pharmacy before injecting.

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (Jastreboff et al.) — PMID 35658024 (2022).
  2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (Frías et al.) — PMID 34170647 (2021).
  3. FDA-Approved Labeling — Mounjaro (tirzepatide) injection, for subcutaneous use. U.S. Food & Drug Administration (2022).

Get tirzepatide through a supervised program.

3-minute assessment. Clinician review within 24 hours. Compounded in the USA by licensed 503A pharmacies.